Sec. 517. Failure to notify of a permanent discontinuance or an interruption
79 words·~1 min read·
/bill/116/hr/925/eah/section-517A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 301 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 331 ) is amended by adding at the end the following: The failure of a manufacturer of a drug described in section 506C(a) or an active pharmaceutical ingredient of such a drug, without a reasonable basis as determined by the Secretary, to notify the Secretary of a permanent discontinuance or an interruption, and the reasons for such discontinuance or interruption, as required by section 506C. .
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Sec. 517
Failure to notify of a permanent discontinuance or an interruption
Cites 1Cited by 0 across 0 sources